• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CytomX Therapeutics, Inc. - Common Stock (NQ:CTMX)

    6.750 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about CytomX Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls ↗
    Analysts turned bullish, citing strong data and the drug's potential to expand into earlier treatment settings. 
    Via Stocktwits
    News headline image
    Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data ↗
    Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway. 
    Via The Motley Fool
    Topics Stocks
    Monday's session: most active stocks ↗
    Via Chartmill
    These stocks are moving in today's session ↗
    Via Chartmill
    CytomX Therapeutics Inc (NASDAQ:CTMX) Soars 56% on Positive Clinical Data Despite Earnings Miss ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
     
    Via Benzinga
    Gapping stocks in Monday's session ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Why CTMX Stock Is Soaring 54% Pre-Market Today? ↗
    CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer. 
    Via Stocktwits
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill
    A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
    Via Chartmill
    News headline image
    CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q3 2025 Earnings Miss, Stock Falls ↗
    CytomX Therapeutics Q3 2025 earnings miss analyst estimates for revenue and EPS, triggering a negative market reaction. 
    Via Chartmill
    Topics Earnings
    News headline image
    CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
     
    Via Benzinga
    News headline image
    Why CytomX Therapeutics Stock Was Skyrocketing This Week ↗
    One pundit believes the company might have a winning cancer drug in its pipeline. 
    Via The Motley Fool
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million. 
    Via Benzinga
    News headline image
    What's going on in today's after hours session ↗
    After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
    Via Chartmill
    News headline image
    Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    CytomX (CTMX) Q2 Revenue Drops 26% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q2 2025 Revenue Beat and Break-Even EPS ↗
    CytomX Therapeutics (CTMX) Q2 2025 revenue beat estimates at $18.66M, with break-even EPS. Shares rose slightly as clinical progress, including CX-2051 data, boosts optimism. 
    Via Chartmill
    News headline image
    This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday ↗
     
    Via Benzinga
    News headline image
    Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗
     
    Via Benzinga
    News headline image
    CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - A Strong Contender in High-Growth Biotech ↗
    CYTOMX THERAPEUTICS (CTMX) meets Minervini’s trend criteria with strong technicals and high-growth fundamentals, making it a candidate for momentum investors. 
    Via Chartmill
    News headline image
    Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗
     
    Via Benzinga
    News headline image
    CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
     
    Via Benzinga
    News headline image
    This CytomX Therapeutics Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday ↗
     
    Via Benzinga
    News headline image
    CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug ↗
    The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses. 
    Via Stocktwits
    News headline image
    Top movers analysis one hour before the close of the markets on 2025-05-12: top gainers and losers in today's session. ↗
    Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
    Via Chartmill
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.